Stockscreener 앱 받기
2.32
0.85%
-0.02
시간 외 거래:
2.35
0.03
+1.29%
Lexicon Pharmaceuticals Inc 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals (LXRX) Completes Phase III Enrollment, Is The 38% Undervaluation Case Convincing? - Sahm
Is Lexicon’s Earnings Slide And New Share Shelf Altering The Investment Case For Lexicon Pharmaceuticals (LXRX)? - simplywall.st
Lexicon Pharmaceuticals (STU:LX31) EV-to-OCF : -14.01 (As of Aug. 15, 2026) - GuruFocus
Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report - simplywall.st
Lexicon Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-08-10 - Seeking Alpha
Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat
Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Issues Positive Forecast for LXRX Earnings - MarketBeat
Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - Yahoo Finance UK
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) Stockholders Plan to Sell 1.26M S - GuruFocus
Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highl - GuruFocus
Lexicon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $3.86, Implies 57% Upside - TradingView
Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ... - Yahoo Finance
Lexicon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Lexicon Pharmaceuticals (Nasdaq: LXRX) files shelf to register 1.26M warrant shares - Stock Titan
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down on Disappointing Earnings - MarketBeat
FMR LLC (LXRX) discloses 11.7% Lexicon Pharmaceuticals stake in amended 13G - Stock Titan
Is Lexicon Pharmaceuticals (LXRX) Facing Challenges After Q2 Ear - GuruFocus
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Lexicon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss - marketscreener.com
Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. Reports Q2 Revenue $692,000, vs. FactSet Est of $4.0M - marketscreener.com
Lexicon: Q2 Earnings Snapshot - marketscreener.com
Lexicon Pharmaceuticals posts Q2 net loss - TradingView
Lexicon Pharmaceuticals Q2 revenue falls to $0.7 million amid clinical updates - Quiver Quantitative
Lexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission - Quiver Quantitative
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - The Manila Times
Lexicon Pharma (Nasdaq: LXRX) swings to $31.8M Q2 2026 loss - Stock Titan
BRIEF-Lexicon Pharmaceuticals Q2 EPS USD -0.07 - TradingView
Lexicon Pharmaceuticals (LXRX) Earnings Date and Reports 2026 $LXRX - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Zacks Research - MarketBeat
Why Lexicon Pharmaceuticals (LXRX) Is Up 6.4% After Completing Randomization in Pivotal SONATA-HCM Trial - Sahm
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Lexicon Pharmaceuticals (LXRX) Slips 1.28% as Shares Hold Above Key SupportLiquidity Order Flow - dars.gov.et
Lexicon Pharmaceuticals Inc (LXRX) Institutional Confidence - TradingKey
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
Lexicon schedules Aug. 6 call and webcast for Q2 results - Stock Titan
Lexicon Pharmaceuticals (LXRX) to Release Earnings on Wednesday - MarketBeat
Lexicon (LXRX) Completes Patient Randomization in Key Phase 3 Tr - GuruFocus
Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment - marketscreener.com
Lexicon's HCM study spans 20 countries; results anticipated Q1 2027 - Stock Titan
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) - Yahoo Finance Australia
Lexicon Pharmaceuticals Inc (LXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexicon Pharmaceuticals Inc - TradingKey
TradingKey - TradingKey
LXRX|Lexicon Pharmaceuticals Inc|Price:2.355|Chg%:+0.065 - TradingKey
Price to sales forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Lexicon Pharmaceuticals Inc (LXRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LXRX|Lexicon Pharmaceuticals Inc|Price:2.290|Chg%:-0.010 - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexicon Pharmaceuticals, Inc. $LXRX Shares Acquired by Siren L.L.C. - MarketBeat
Price to earnings forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Enterprise value to EBITDA forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Price to book forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Lexicon Pharmaceuticals Inc. (LXRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders - simplywall.st
Lexicon Pharmaceuticals outlines its path in gastrointestinal disease. Drug pipeline and Nasdaq list - ad-hoc-news.de
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally - ChartMill
Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin - Ad-hoc-news.de
Lexicon Pharmaceuticals (LXRX) Gains 3.88% as Stock Tests Key ResistanceStop Loss Guidance - DonanımHaber
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
0.52%
0.07%
자본화:
|
볼륨(24시간):